RCUS

insider transactions

Arcus Biosciences, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-48.7K

0 buy · 48.7K sell

Net value · 365d

-$1.1M

$0 in · $1.1M out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 48.7K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Exercise·M
Jun 11, 26

Carolyn C. Tang

General Counsel

$87.7K

34.1K sh · $2.57

Own New
Exercise·M
Jun 11, 26

Carolyn C. Tang

General Counsel

$87.7K

34.1K sh · $2.57

Own +23%
Grant·A
Jun 11, 26

Antoni Ribas

Director

$0

16.9K sh

Own New
Grant·A
Jun 11, 26

Antoni Ribas

Director

$0

5.7K sh

Own +15%
Grant·A
Jun 11, 26

Nicole Lambert

Director

$0

16.9K sh

Own New
Grant·A
Jun 11, 26

Nicole Lambert

Director

$0

5.7K sh

Own +15%
Grant·A
Jun 11, 26

David L. Lacey

Director

$0

16.9K sh

Own New
Grant·A
Jun 11, 26

David L. Lacey

Director

$0

5.7K sh

Own +8%
Grant·A
Jun 11, 26

Patrick Machado

Director

$0

16.9K sh

Own New
Grant·A
Jun 11, 26

Patrick Machado

Director

$0

5.7K sh

Own +15%
Grant·A
Jun 11, 26

Yasunori Kaneko

Director

$0

16.9K sh

Own New
Grant·A
Jun 11, 26

Yasunori Kaneko

Director

$0

5.7K sh

Own +28%
Grant·A
Jun 11, 26

Kathryn E Falberg

Director

$0

16.9K sh

Own New
Grant·A
Jun 11, 26

Kathryn E Falberg

Director

$0

5.7K sh

Own +15%
Grant·A
Jun 11, 26

Andrew J Perlman

Director

$0

16.9K sh

Own New
Grant·A
Jun 11, 26

Andrew J Perlman

Director

$0

5.7K sh

Own +13%
Sell·S
Jun 1, 26

Alexander Azoy

Chief Accounting Officer · 10b5-1

$66.0K

2.6K sh · $25.77

Own -6%
Sell·S
May 11, 26

Robert C. Goeltz II KEY

Chief Financial Officer · 10b5-1

$199.0K

7.8K sh · $25.63

Own -8%
Grant·A
Jan 23, 26

Richard Markus

Chief Medical Officer

$0

96.0K sh

Own New
Grant·A
Jan 23, 26

Richard Markus

Chief Medical Officer

$0

24.0K sh

Own +37%
Grant·A
Jan 23, 26

Carolyn C. Tang

General Counsel

$0

96.0K sh

Own New
Grant·A
Jan 23, 26

Carolyn C. Tang

General Counsel

$0

24.0K sh

Own +19%
Grant·A
Jan 23, 26

Alexander Azoy

Chief Accounting Officer

$0

14.1K sh

Own New
Grant·A
Jan 23, 26

Alexander Azoy

Chief Accounting Officer

$0

21.1K sh

Own +114%
Grant·A
Jan 23, 26

Jennifer Jarrett

Chief Operating Officer

$0

126.0K sh

Own New
Grant·A
Jan 23, 26

Jennifer Jarrett

Chief Operating Officer

$0

31.0K sh

Own +16%
Grant·A
Jan 23, 26

Robert C. Goeltz II KEY

Chief Financial Officer

$0

96.0K sh

Own New
Grant·A
Jan 23, 26

Robert C. Goeltz II KEY

Chief Financial Officer

$0

24.0K sh

Own +35%
Grant·A
Jan 23, 26

Juan C. Jaen KEY

President

$0

126.0K sh

Own New
Grant·A
Jan 23, 26

Juan C. Jaen KEY

President

$0

31.0K sh

Own +9%
Grant·A
Jan 23, 26

Terry J Rosen KEY

Chief Executive Officer

$0

315.0K sh

Own New
Grant·A
Jan 23, 26

Terry J Rosen KEY

Chief Executive Officer

$0

79.0K sh

Own +4%
Other·G
Jan 8, 26

Terry J Rosen KEY

Chief Executive Officer

$0

35.0K sh

Own -2%
Sell·S
Jan 5, 26

Juan C. Jaen KEY

President · 10b5-1

$2.3K

100 sh · $23.20

Own -0%
Sell·S
Jan 5, 26

Juan C. Jaen KEY

President · 10b5-1

$45.9K

2.1K sh · $22.34

Own -0%
Sell·S
Jan 5, 26

Juan C. Jaen KEY

President · 10b5-1

$633.2K

29.7K sh · $21.34

Own -3%
Sell·S
Dec 31, 25

Robert C. Goeltz II KEY

Chief Financial Officer · 10b5-1

$153.2K

6.6K sh · $23.38

Own -9%
Other·G
Dec 30, 25

Terry J Rosen KEY

Chief Executive Officer

$0

2.4K sh

Own -0%
Other·G
Dec 16, 25

Antoni Ribas

Director

$0

5.0K sh

Own -12%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 11, 2026	Carolyn C. Tang	General Counsel	Exercise M	34.1K	New	$2.57	$87.7K
Jun 11, 2026	Carolyn C. Tang	General Counsel	Exercise M	34.1K	+23%	$2.57	$87.7K
Jun 11, 2026	Antoni Ribas	Director	Grant A	16.9K	New	—	$0
Jun 11, 2026	Antoni Ribas	Director	Grant A	5.7K	+15%	—	$0
Jun 11, 2026	Nicole Lambert	Director	Grant A	16.9K	New	—	$0
Jun 11, 2026	Nicole Lambert	Director	Grant A	5.7K	+15%	—	$0
Jun 11, 2026	David L. Lacey	Director	Grant A	16.9K	New	—	$0
Jun 11, 2026	David L. Lacey	Director	Grant A	5.7K	+8%	—	$0
Jun 11, 2026	Patrick Machado	Director	Grant A	16.9K	New	—	$0
Jun 11, 2026	Patrick Machado	Director	Grant A	5.7K	+15%	—	$0
Jun 11, 2026	Yasunori Kaneko	Director	Grant A	16.9K	New	—	$0
Jun 11, 2026	Yasunori Kaneko	Director	Grant A	5.7K	+28%	—	$0
Jun 11, 2026	Kathryn E Falberg	Director	Grant A	16.9K	New	—	$0
Jun 11, 2026	Kathryn E Falberg	Director	Grant A	5.7K	+15%	—	$0
Jun 11, 2026	Andrew J Perlman	Director	Grant A	16.9K	New	—	$0
Jun 11, 2026	Andrew J Perlman	Director	Grant A	5.7K	+13%	—	$0
Jun 1, 2026	Alexander Azoy 10b5-1	Chief Accounting Officer	Sell S	2.6K	-6%	$25.77	$66.0K
May 11, 2026	Robert C. Goeltz II KEY 10b5-1	Chief Financial Officer	Sell S	7.8K	-8%	$25.63	$199.0K
Jan 23, 2026	Richard Markus	Chief Medical Officer	Grant A	96.0K	New	—	$0
Jan 23, 2026	Richard Markus	Chief Medical Officer	Grant A	24.0K	+37%	—	$0
Jan 23, 2026	Carolyn C. Tang	General Counsel	Grant A	96.0K	New	—	$0
Jan 23, 2026	Carolyn C. Tang	General Counsel	Grant A	24.0K	+19%	—	$0
Jan 23, 2026	Alexander Azoy	Chief Accounting Officer	Grant A	14.1K	New	—	$0
Jan 23, 2026	Alexander Azoy	Chief Accounting Officer	Grant A	21.1K	+114%	—	$0
Jan 23, 2026	Jennifer Jarrett	Chief Operating Officer	Grant A	126.0K	New	—	$0
Jan 23, 2026	Jennifer Jarrett	Chief Operating Officer	Grant A	31.0K	+16%	—	$0
Jan 23, 2026	Robert C. Goeltz II KEY	Chief Financial Officer	Grant A	96.0K	New	—	$0
Jan 23, 2026	Robert C. Goeltz II KEY	Chief Financial Officer	Grant A	24.0K	+35%	—	$0
Jan 23, 2026	Juan C. Jaen KEY	President	Grant A	126.0K	New	—	$0
Jan 23, 2026	Juan C. Jaen KEY	President	Grant A	31.0K	+9%	—	$0
Jan 23, 2026	Terry J Rosen KEY	Chief Executive Officer	Grant A	315.0K	New	—	$0
Jan 23, 2026	Terry J Rosen KEY	Chief Executive Officer	Grant A	79.0K	+4%	—	$0
Jan 8, 2026	Terry J Rosen KEY	Chief Executive Officer	Other G	35.0K	-2%	—	$0
Jan 5, 2026	Juan C. Jaen KEY 10b5-1	President	Sell S	100	-0%	$23.20	$2.3K
Jan 5, 2026	Juan C. Jaen KEY 10b5-1	President	Sell S	2.1K	-0%	$22.34	$45.9K
Jan 5, 2026	Juan C. Jaen KEY 10b5-1	President	Sell S	29.7K	-3%	$21.34	$633.2K
Dec 31, 2025	Robert C. Goeltz II KEY 10b5-1	Chief Financial Officer	Sell S	6.6K	-9%	$23.38	$153.2K
Dec 30, 2025	Terry J Rosen KEY	Chief Executive Officer	Other G	2.4K	-0%	—	$0
Dec 16, 2025	Antoni Ribas	Director	Other G	5.0K	-12%	—	$0

About RCUS insider trading

This page tracks insider transactions for Arcus Biosciences, Inc. (RCUS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.